Could Retatrutide Be Worth $10 Billion to Eli Lilly?
The company continues to dominate the weight loss market.
Overview
Eli Lilly (NYSE:LLY) is posting excellent financial results, with tirzepatide, a medicine that has earned indications for diabetes, weight management, and obstructive sleep apnea (OSA), currently the company's biggest growth driver. Tirzepatide was a breakthrough. It became the first approved therapy to mimic the actions of the GLP-1 and GIP gut hormones, a mechanism of action that likely contributes to its greater effectiveness than its biggest competitor, semaglutide.
However, Eli Lilly has several pipeline candidates in this area that could strengthen its position, and one of them is retatrutide. This compound isn't approved yet, but it is already generating plenty of buzz, with some analysts expecting it to generate up to $25 billion in peak annual sales. Let's find out why there is so much excitement surrounding retatrutide and what investors should do about it.
Image source: The Motley Fool.
Details
Source
Originally published at www.fool.com.